Ivonescimab

8 trials 5 recruiting

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

5 Recruiting

1 Completed trials

5 Sponsors

11 Countries

Phase III

Phase II

Phase III: 5 Phase II: 3

Oversight events:

1 corrective measure across 1 trial

View oversight register →

Indications tested

Non-small cell lung cancer metastatic 2 Biliary cancer metastatic 1 Pleural mesothelioma malignant 1 Lung squamous cell carcinoma stage IV 1 Lung squamous cell carcinoma stage III 1

Sponsors using this IMP

Summit Therapeutics Inc. 3 Unicancer 2 Groupe Oncologie Radiotherapie Tete Cou 1 Intergroupe Francophone De Cancerologie Thoracique 1 Summit Therapeutics Sub Inc. 1

All trials

8 total

HARMONi-3 Not authorised

2023-504989-37-00 Phase III 7 countries Summit Therapeutics Sub Inc.
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu… Pending

2025-521587-35-00 Phase III 8 countries Summit Therapeutics Inc.
Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and… Recruiting

2025-522996-27-00 Phase III 3 countries Groupe Oncologie Radiotherapie Tete Cou
Testing ivonescimab in combination with standard chemotherapy in advanced or metastatic gastric and gastroesophageal adenocarcinoma patients Recruiting

2025-520694-39-00 Phase II 1 country Unicancer
Testing ivonescimab versus FOLFOX in advanced biliary tract cancer patients Recruiting

2024-515875-36-00 Phase II 1 country Unicancer
Evaluating ivonescimab as a potential treatment for pleural mesothelioma patients whose cancer has returned after previous immunotherapy and… Recruiting

2024-519052-82-00 Phase II 1 country Intergroupe Francophone De Cancerologie Thoracique
HARMONi-3 Recruiting

2024-513087-26-00 Phase III 9 countries Summit Therapeutics Inc.
Effect of study drug combined with chemotherapy in patients with locally advanced or metastatic lung cancer with mutated receptor responsibl… Ended

2023-504434-22-00 Phase III 3 countries Summit Therapeutics Inc.

Showing 1–8 of 8 trials

← All drugs A–Z